LUNG vs TMCI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

LUNG

66.6
AI Score
VS
LUNG Wins

TMCI

56.8
AI Score

Investment Advisor Scores

LUNG

67score
Recommendation
BUY

TMCI

57score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric LUNG TMCI Winner
Revenue 43.34M 92.57M TMCI
Net Income -23.73M -33.83M LUNG
Gross Margin 78.0% 78.9% TMCI
Net Margin -54.8% -36.5% TMCI
Operating Income -22.01M -32.13M LUNG
ROE -60.6% -49.9% TMCI
ROA -20.7% -18.7% TMCI
Total Assets 114.73M 181.06M TMCI
Cash 55.84M 12.61M LUNG
Debt/Equity 0.96 0.83 TMCI
Current Ratio 4.32 2.90 LUNG
Free Cash Flow -15.32M -2.72M TMCI

Relative Price Performance (Last 90 Days)

LUNG 1M: -15.8% · 3M: +29.7% TMCI 1M: -5.9% · 3M: +2.9%

Current Technical Phase

LUNG

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 45

RSI (14): 44.8 · Price: $1.92

TMCI

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 43

RSI (14): 42.5 · Price: $4.33

Fundamentals Snapshot

Metric LUNG TMCI
Market Cap — —
Forward P/E -2.0 -5.1
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin 0.8% 0.8%
Operating Margin -0.4% -0.3%
EPS -1.15 -0.92
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, LUNG is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.